EPS for Apogee Enterprises, Inc. (APOG) Expected At $0.97; 5 Analysts Are Bullish AstraZeneca PLC (LON:AZN) Last Week

AstraZeneca PLC (LON:AZN) Logo

Analysts expect Apogee Enterprises, Inc. (NASDAQ:APOG) to report $0.97 EPS on April, 11.They anticipate $0.14 EPS change or 16.87% from last quarter’s $0.83 EPS. APOG’s profit would be $26.36M giving it 9.86 P/E if the $0.97 EPS is correct. After having $0.80 EPS previously, Apogee Enterprises, Inc.’s analysts see 21.25% EPS growth. The stock increased 0.05% or $0.02 during the last trading session, reaching $38.24. About 159,405 shares traded. Apogee Enterprises, Inc. (NASDAQ:APOG) has declined 16.34% since April 3, 2018 and is downtrending. It has underperformed by 20.71% the S&P500. Some Historical APOG News: 12/04/2018 – APOGEE ENTERPRISES – ARCHITECTURAL SERVICES SEGMENT HAS BACKLOG, ORDER PIPELINE “STRENGTH TO SUPPORT” OUTLOOK FOR GROWTH IN FISCAL YEARS 2019 & 2020; 12/04/2018 – APOGEE ENTERPRISES INC SEES 2019 ADJUSTED OPERATING MARGIN OF 9.1 PCT TO 9.6 PCT; 12/04/2018 – Apogee Enterprises Sees Top Line Growing About 10 % in FY19; 12/04/2018 – Apogee Enterprises 4Q Net $22.3M; 12/04/2018 – APOGEE ENTERPRISES INC APOG.O SEES FY 2019 ADJUSTED SHR $3.43 TO $3.63; 17/04/2018 – Engaged Capital Takes Apogee Stake in Push to End Buying Spree; 12/04/2018 – APOGEE ENTERPRISES INC – FOURTH-QUARTER SEGMENT BACKLOG WAS $405.7 MLN; 12/04/2018 – APOGEE SEES 2019 ADJ. EPS $3.43 TO $3.63, EST. $4.05; 17/04/2018 – ENGAGED CAPITAL REPORTS 6 PCT STAKE IN APOGEE ENTERPRISES AS OF APRIL 12 – SEC FILING; 17/04/2018 – MEDIA-Activist investor Engaged Capital takes stake in Apogee – Bloomberg

Among 8 analysts covering AstraZeneca PLC (LON:AZN), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. AstraZeneca PLC has GBX 8500 highest and GBX 5000 lowest target. GBX 6390.40’s average target is 3.44% above currents GBX 6178 stock price. AstraZeneca PLC had 63 analyst reports since October 8, 2018 according to SRatingsIntel. Shore Capital maintained the stock with “Hold” rating in Thursday, November 8 report. The rating was maintained by Barclays Capital with “Overweight” on Monday, October 15. As per Monday, October 29, the company rating was maintained by Credit Suisse. The stock of AstraZeneca PLC (LON:AZN) has “Buy” rating given on Monday, February 18 by Deutsche Bank. Societe Generale maintained the stock with “Buy” rating in Wednesday, January 16 report. The rating was maintained by Barclays Capital with “Overweight” on Friday, December 7. The rating was maintained by Shore Capital with “Hold” on Monday, October 22. The stock has “Outperform” rating by Credit Suisse on Thursday, November 1. Morgan Stanley maintained AstraZeneca PLC (LON:AZN) rating on Friday, December 14. Morgan Stanley has “Equal Weight” rating and GBX 6400 target. The stock has “Hold” rating by Shore Capital on Friday, November 16. See AstraZeneca PLC (LON:AZN) latest ratings:

02/04/2019 Broker: HSBC Rating: Reduce Old Target: GBX 5140.00 New Target: GBX 5180.00 Maintain
01/04/2019 Broker: Barclays Capital Rating: Overweight Old Target: GBX 6800.00 New Target: GBX 7000.00 Maintain
01/04/2019 Broker: UBS Rating: Neutral Old Target: GBX 5900.00 Maintain
01/04/2019 Broker: Deutsche Bank Rating: Buy Old Target: GBX 6900.00 Maintain
29/03/2019 Broker: Bryan Garnier & Cie Rating: Neutral Old Target: GBX 6220.00 Maintain
29/03/2019 Broker: Shore Capital Rating: Buy Maintain
29/03/2019 Broker: Liberum Capital Rating: Hold Old Target: GBX 5800.00 Maintain
20/03/2019 Broker: Liberum Capital Rating: Hold Old Target: GBX 5800.00 Maintain
18/03/2019 Broker: Goldman Sachs Rating: Sell Maintain
14/03/2019 Broker: Jefferies Rating: Hold Old Target: GBX 6400.00 Maintain

Investors sentiment increased to 1.24 in Q4 2018. Its up 0.19, from 1.05 in 2018Q3. It increased, as 27 investors sold Apogee Enterprises, Inc. shares while 52 reduced holdings. 37 funds opened positions while 61 raised stakes. 24.70 million shares or 4.00% less from 25.73 million shares in 2018Q3 were reported. Delphi Mgmt Ma reported 11,645 shares. State Of Tennessee Treasury Department, a Tennessee-based fund reported 21,958 shares. 1.21 million are held by State Street. Stone Ridge Asset Mngmt Lc reported 0.04% in Apogee Enterprises, Inc. (NASDAQ:APOG). Envestnet Asset has invested 0% of its portfolio in Apogee Enterprises, Inc. (NASDAQ:APOG). State Board Of Administration Of Florida Retirement has 20,748 shares for 0% of their portfolio. Principal Fincl Grp Inc reported 228,800 shares. 371,300 were reported by Prudential Public Limited Com. Pinebridge L P holds 9,819 shares. Mutual Of America Ltd Co owns 707 shares. Tiaa Cref Inv Limited Liability stated it has 0% of its portfolio in Apogee Enterprises, Inc. (NASDAQ:APOG). Connecticut-based Aqr Capital Management Ltd has invested 0% in Apogee Enterprises, Inc. (NASDAQ:APOG). Northern Corporation holds 377,785 shares or 0% of its portfolio. Pennsylvania-based Commonwealth Of Pennsylvania Pub School Empls Retrmt has invested 0.01% in Apogee Enterprises, Inc. (NASDAQ:APOG). Tocqueville Asset Management Limited Partnership holds 227,900 shares or 0.1% of its portfolio.

Since October 29, 2018, it had 3 insider buys, and 0 insider sales for $559,526 activity. $269,650 worth of Apogee Enterprises, Inc. (NASDAQ:APOG) was bought by Puishys Joseph F. on Monday, December 24. Another trade for 2,000 shares valued at $56,205 was made by PORTER JAMES S on Monday, December 24. Parker Herbert K had bought 7,000 shares worth $233,671 on Monday, October 29.

More notable recent Apogee Enterprises, Inc. (NASDAQ:APOG) news were published by: Nasdaq.com which released: “Apogee (APOG) Up 23% YTD After 35% Drop in 2018: What’s Next? – Nasdaq” on March 28, 2019, also Forbes.com with their article: “Small Caps And Big Tech Dominate The Nasdaq, And These 5 Stocks Are Especially Interesting – Forbes” published on March 18, 2019, Seekingalpha.com published: “Apogee declares $0.175 dividend – Seeking Alpha” on January 17, 2019. More interesting news about Apogee Enterprises, Inc. (NASDAQ:APOG) were released by: Nasdaq.com and their article: “Apogee Enterprises (APOG) Misses Q3 Earnings and Revenue Estimates – Nasdaq” published on December 20, 2018 as well as Nasdaq.com‘s news article titled: “What’s in Store for Apogee (APOG) Stock in Q2 Earnings? – Nasdaq” with publication date: September 14, 2018.

Apogee Enterprises, Inc. designs and develops glass services and products in the United States, Canada, and Brazil. The company has market cap of $1.04 billion. The firm operates through four divisions: Architectural Glass, Architectural Framing Systems, Architectural Services, and Large-Scale Optical Technologies . It has a 13.55 P/E ratio. The Architectural Glass segment fabricates coated and high-performance glass used in customized windows and wall systems comprising the outside skin of commercial, institutional, and multi-family residential buildings.

More recent AstraZeneca PLC (LON:AZN) news were published by: which released: “How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock? – Yahoo Finance” on June 01, 2018. Also published the news titled: “What Investors Should Know About AstraZeneca PLC’s (LON:AZN) Financial Strength – Yahoo Finance” on December 25, 2017. Globenewswire.com‘s news article titled: “Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results – GlobeNewswire” with publication date: November 29, 2018 was also an interesting one.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 81.04 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 36.34 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

The stock decreased 1.39% or GBX 87 during the last trading session, reaching GBX 6178. About 536,011 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since April 3, 2018 and is . It has underperformed by 4.37% the S&P500. Some Historical AZN News: 08/05/2018 – AstraZeneca: Approval for Treatment of Relapsed Ovarian Cancer; 08/05/2018 – ASTRAZENECA AZN EMA OKS LYNPARZA: MAINTENANCE OVARIAN CANCER; 21/05/2018 – INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV — THE NO. 1 SEXUALLY TRANSMITTED DISEASE; 24/04/2018 – REDX PHARMA PLC – REDX APPOINTS SENIOR ASTRAZENECA EXECUTIVE AS CEO; 06/04/2018 – CLVS CONFIRMS EXPANDED FDA LABEL FOR RUBRACA IN OVARIAN CANCER; 25/05/2018 – IMFINZI(R) (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer; 25/05/2018 – Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales; 25/05/2018 – AstraZeneca: Clinically-meaningful Improvement in Patients Receiving Imfinzi Compared to Placebo; 12/03/2018 – STAT Plus: Pharmalittle: Glaxo wins a reprieve for Advair; AstraZeneca delays lung cancer trial results; 17/05/2018 – AstraZeneca Pharmaceuticals LP | olaparib | N/A | 05/15/2018 | Treatment of primary peritoneal cancer | Designated | NFDA | N/A | | N/A

Apogee Enterprises, Inc. (NASDAQ:APOG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.